Abstract:Major histocompatibility complex (MHC) class II molecules are membrane-anchored heterodimers that present antigenic peptides to T cells. Expression of these molecules in soluble form has met limited success, presumably due to their large size, heterodimeric structure and the presence of multiple disulfide bonds. Here we have used directed evolution and yeast surface display to engineer soluble single-chain human lymphocyte antigen (HLA) class II MHC DR1 molecules without covalently attached peptides (scDR1αβ). Specifically, a library of mutant scDR1αβ molecules was generated by random mutagenesis and screened by fluorescence activated cell sorting (FACS) with DR-specific conformation-sensitive antibodies, yielding three well-expressed and properly folded scDR1αβ variants displayed on the yeast cell surface. Detailed analysis of these evolved variants and a few site-directed mutants generated de novo indicated three amino acid residues in the β1 domain are important for the improved protein folding yield. Further, molecular modeling studies suggested these mutations might increase the protein folding efficiency by improving the packing of a hydrophobic core in the α1β1 domain of DR1. The scDR1αβ mutants displayed on the yeast cell surface are remarkably stable and bind specifically to DR-specific peptide HA306–318 with high sensitivity and rapid kinetics in flow cytometric assays. Moreover, since the expression, stability and peptide-binding properties of these mutants can be directly assayed on the yeast cell surface using immuno-fluorescence labeling and flow cytometry, time-consuming purification and refolding steps of recombinant DR1 molecules are eliminated. Therefore, these scDR1αβ molecules will provide a powerful technology platform for further design of DR1 molecules with improved peptide-binding specificity and affinity for therapeutic and diagnostic applications. The methods described here should be generally applicable to other class II MHC molecules and also class I MHC molecules for their functional expression, characterization and engineering.

Directed Evolution of Soluble Single-chain Human Class II MHC Molecules

Cell Surface Display of Functional Human MHC Class II Proteins: Yeast Display Versus Insect Cell Display.

Use of Baculovirus MHC/peptide Display Libraries to Characterize T‐cell Receptor Ligands

Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.

Recombinant Expression of the<i>β</i>-Subunit of HLA-DR10 for the Selection of Novel Lymphoma Targeting Molecules

Increased yields and biological potency of knob-into-hole-based soluble MHC class II molecules

Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA)

A general platform for targeting MHC-II antigens via a single loop

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes

Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol

In vitro and ex vivo functional characterization of human HLA-DRB1∗04 restricted T cell receptors

Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments

Directed Evolution Using Stabilized Bacterial Peptide Display

Development of a Stable Peptide-Major Histocompatibility Complex (MHC) via Sortase and Click Chemistry

Validation of novel conditional ligands and large-scale detection of antigen-specific T cells for H-2Dd and H-2Kd

Employing a Recombinant HLA-DR3 Expression System to Dissect Major Histocompatibility Complex II-Thyroglobulin Peptide Dynamism

Cloning, expression, and purification of HLA-A2-BSP and β-2m in Escherichia coli

Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae

Conformational and structural characteristics of peptides binding to HLA-DR molecules.

Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins

Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition